ON ONWD ONWARD Medical N.V. Loading... : Bullish and Bearish Analyst Opinions

Author bought 5000 ONWD shares betting that ONWARD Medical's ARC-EX commercial traction (H1 revenue +240% YoY, 159 systems via paid evaluations, 130+ US clinics, moving into home use) plus optionality from ARC-IM and ARC-BCI clinical programs can turn it into a much bigger story than a small medical device company. The catalyst is continued clinical trial success and commercial rollout; the main stated risk is heavy cash burn and the possibility the big programs fail.

Author bought ONWARD Medical after H1 results showed ARC-EX commercialization ramping: 159 systems sold/supplied in H1 2026 (up 430% YoY), ARC-EX revenue of €3.4m (up 240%), and availability in 130+ US clinics, with expansion into home use including the Veterans Affairs system. The bull case rests on ARC-EX providing near-term commercial revenue while ARC-IM (Empower BP pivotal study with 22 participants across 14 sites, plus EIGER and Parkinson's/bladder work) and ARC-BCI (seven implants) offer larger optionality if clinical results hold. Financially the company posted a €23.3m H1 operating loss but holds €81.5m cash after a €40.6m April raise plus a BlackRock facility up to €50m, giving execution runway. Main risks are continued losses and dependence on clinical and commercial execution; author plans to hold for a while.